ETON
Eton Pharmaceuticals, Inc.Company Information
- Company Name
- Eton Pharmaceuticals, Inc.
- CIK
- CIK0001710340
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ETON: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ETON
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-10
- Last sale
- 2026-08-28
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 410,701
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 19,691,129
- Shares outstanding
- 27,642,000
- Ownership
- 71.24%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 43.26%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 27 | 20 | 26 | 37 | 25 | 17 | 15 | 20 | 18 | 17 | 21 | 22 | ||||||
| Accounts Receivable Net Current | 25 | 13 | 12 | 13 | 14 | 16 | 5 | 6 | 5 | 4 | 3 | 3 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 69 | 53 | 61 | 72 | 68 | 50 | 41 | 30 | 25 | 24 | 27 | 27 | ||||||
| Inventory Net | 10 | 14 | 15 | 17 | 24 | 14 | 15 | 2 | 2 | 2 | 1 | 1 | ||||||
| Prepaid Expense And Other Assets Current | 7 | 6 | 7 | 5 | 5 | 3 | 5 | 2 | 1 | 1 | 1 | 1 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 46 | 44 | 31 | 32 | 33 | 34 | 35 | 6 | 6 | 6 | 5 | 4 | ||||||
| Operating Lease Right Of Use Asset | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 116 | 98 | 92 | 105 | 102 | 84 | 76 | 36 | 32 | 31 | 32 | 32 | ||||||
| Accounts Payable Current | 14 | 13 | 11 | 14 | 12 | 5 | 4 | 3 | 2 | 2 | 2 | 2 | ||||||
| Long Term Debt Current | - | - | 9 | - | - | - | 0 | 4 | 5 | 5 | 5 | 2 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 45 | 44 | 38 | 44 | 39 | 25 | 20 | 20 | 18 | 15 | 16 | 10 | ||||||
| Other Accrued Liabilities Current | - | - | - | - | - | - | - | 5 | - | - | - | - | ||||||
| Debt Current | 9 | 12 | - | 3 | 3 | - | - | - | - | - | - | - | ||||||
| Accrued Liabilities Current | 11 | 8 | 9 | 9 | 7 | 8 | 9 | - | 11 | 8 | 5 | 7 | ||||||
| Long Term Debt | - | - | - | - | - | 30 | 30 | - | - | - | 0 | 4 | ||||||
| Long Term Debt Noncurrent | 19 | 19 | 22 | 28 | 27 | - | 30 | - | - | - | - | - | ||||||
| Operating Lease Liability Noncurrent | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Payable And Accrued Liabilities Noncurrent | - | - | - | 5 | 7 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | 4 | 4 | 5 | 4 | 4 | 4 | 2 | - | - | - | 0 | - | ||||||
| Liabilities | 69 | 67 | 66 | 81 | 78 | 60 | 52 | 20 | 18 | 15 | 16 | 15 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 146 | 142 | 139 | 137 | 136 | 134 | 132 | 123 | 121 | 120 | 120 | 119 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 47 | 31 | 26 | 23 | 24 | 24 | 24 | 16 | 13 | 15 | 15 | 17 | ||||||
| Retained Earnings Accumulated Deficit | -99 | -111 | -112 | -114 | -112 | -109 | -108 | -107 | -108 | -105 | -104 | -102 | ||||||
| Liabilities And Stockholders Equity | 116 | 98 | 92 | 105 | 102 | 84 | 76 | 36 | 32 | 31 | 32 | 32 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | 50 | ||||||
| Common Stock Shares Issued | 28 | 27 | 27 | 27 | 27 | 27 | 27 | 26 | 26 | 26 | 26 | 26 | ||||||
| Shares Outstanding | 28 | 27 | 27 | 27 | 27 | 27 | 27 | 26 | 26 | 26 | 26 | 26 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEton Pharmaceuticals, Inc. (ETON) — SEC Financial Statements & Analysis
Eton Pharmaceuticals, Inc. (ETON) is a pharmaceutical preparations company, incorporated in DE. Eton Pharmaceuticals, Inc. trades on Nasdaq as: ETON. Eton Pharmaceuticals, Inc. (ETON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Eton Pharmaceuticals, Inc. carries a market cap of $1.00B, a P/E ratio of 78.87x, a P/B ratio of 21.48x, a P/S ratio of 9.48x, an enterprise value of $1.00B, and an EV/EBITDA multiple of 48.04x. On profitability, it posts a gross margin of 57.87%, an operating margin of 15.44%, a net margin of 12.02%, a Return on Equity (ROE) of 35.97%, a Return on Assets (ROA) of 11.67%, and a Return on Invested Capital (ROIC) of 40.73%. Per share, it reports EPS of $0.46, diluted EPS of $0.39, free cash flow per share of $0.53, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 81.49% year-over-year, net income growth of -407.36% year-over-year, and EPS growth of -399.04% year-over-year. On the balance sheet, it maintains a current ratio of 1.52x, a quick ratio of 1.15x, working capital of $23.48M, a debt-to-equity ratio of 1.49x, a debt ratio of 0.6, an interest coverage ratio of 6.50x, free cash flow of $14.72M (TTM), and net debt of $1.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.00B
- P/E TTM
- 78.87x
- EPS TTM
- $0.46
- P/B TTM
- 21.48x
- ROE TTM
- 35.97%
- ROA TTM
- 11.67%
- Debt To Equity
- 1.49x
- Free Cash Flow TTM
- $14.72M
- Net Revenue TTM Growth 1Y
- 81.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Eton Pharmaceuticals, Inc. in?
Eton Pharmaceuticals, Inc. (ETON) operates in the Pharmaceutical Preparations industry.
What exchange does ETON trade on?
Eton Pharmaceuticals, Inc. (ETON) trades on the Nasdaq.
Where is Eton Pharmaceuticals, Inc. incorporated?
Eton Pharmaceuticals, Inc. is incorporated in DE.
When was Eton Pharmaceuticals, Inc. (ETON)'s most recent SEC filing?
Eton Pharmaceuticals, Inc. (ETON)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ETON's market cap?
Eton Pharmaceuticals, Inc. (ETON) has a market capitalization of $1.00B as of 2026-06-30.
What is ETON's P/E ratio?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month P/E ratio is 78.87x as of 2026-06-30.
What is ETON's EPS (earnings per share)?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month EPS is $0.46 as of 2026-06-30.
What is ETON's ROE (return on equity)?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month Return on Equity (ROE) is 35.97% as of 2026-06-30.
What is ETON's ROA (return on assets)?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month Return on Assets (ROA) is 11.67% as of 2026-06-30.
What is ETON's ROIC (return on invested capital)?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month Return on Invested Capital (ROIC) is 40.73% as of 2026-06-30.
What is ETON's EV/EBITDA?
Eton Pharmaceuticals, Inc. (ETON)'s trailing twelve month EV/EBITDA is 48.04x as of 2026-06-30.